IPP Bureau

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

By IPP Bureau - August 16, 2023

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.

Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP

By IPP Bureau - August 16, 2023

Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).

Mobile addicted generation heading towards hearing disorders: Survey
Mobile addicted generation heading towards hearing disorders: Survey

By IPP Bureau - August 16, 2023

The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests

By IPP Bureau - August 16, 2023

CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions

Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma

By IPP Bureau - August 16, 2023

ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity

Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression
Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression

By IPP Bureau - August 16, 2023

Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA

Exor to buy 15% shareholding in Philips
Exor to buy 15% shareholding in Philips

By IPP Bureau - August 16, 2023

Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases

BioNTech appointing James Ryan as Chief Legal Officer
BioNTech appointing James Ryan as Chief Legal Officer

By IPP Bureau - August 16, 2023

Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry

Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat
Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat

By IPP Bureau - August 16, 2023

Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus

Dr Srikanth Ramaswamy bags Lister Prize to fund brain research
Dr Srikanth Ramaswamy bags Lister Prize to fund brain research

By IPP Bureau - August 16, 2023

Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize

Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery
Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery

By IPP Bureau - August 16, 2023

Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets

Eugia Pharma receives USFDA Approval for Icatibant Injection
Eugia Pharma receives USFDA Approval for Icatibant Injection

By IPP Bureau - August 16, 2023

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities

National Medical Library has a pivotal role to play in making medical education accessible to all via digital platform: Dr Pawar
National Medical Library has a pivotal role to play in making medical education accessible to all via digital platform: Dr Pawar

By IPP Bureau - August 14, 2023

Continuous learning is not just an option but a responsibility that every healthcare professional must shoulder

Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr
Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr

By IPP Bureau - August 13, 2023

Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023

Krsnaa Diagnostics posts Q1 FY24 consolidated PAT at Rs. 14.64 Cr
Krsnaa Diagnostics posts Q1 FY24 consolidated PAT at Rs. 14.64 Cr

By IPP Bureau - August 13, 2023

Krsnaa Diagnostics has reported total income of Rs. 143.80 crores during the period ended June 30, 2023

Latest Stories

Interviews

Packaging